Quality-Adjusted Survival Analysis of Neurologic Events with Cilta-Cel Versus Standard of Care in Patients with Lenalidomide-Refractory Multiple Myeloma Who Received 1–3 Prior Lines of Therapy: CARTITUDE-4 Trial Population

Key Points

• Quality-adjusted survival was notably better with cilta-cel compared to standard of care.
• Patients treated with cilta-cel experienced a significant reduction in neurologic events during the trial.
• Analysis employed a comparison of treatment regimens in a cohort of lenalidomide-refractory multiple myeloma patients.
• Findings indicate a need for further exploration into cilta-cel's role in enhancing patient outcomes.